MULTIPLE MYELOMA IN RELAPSE
Clinical trials for MULTIPLE MYELOMA IN RELAPSE explained in plain language.
Never miss a new study
Get alerted when new MULTIPLE MYELOMA IN RELAPSE trials appear
Sign up with your email to follow new studies for MULTIPLE MYELOMA IN RELAPSE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cocktail aims to tame returning bone marrow cancer
Disease control Recruiting nowThis study tests whether adding daratumumab to a standard three-drug regimen can shrink tumors in people whose multiple myeloma has returned or stopped responding to prior treatments. About 43 adults aged 18 to 80 will receive the four drugs in cycles. The main goal is to see how…
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE2 • Sponsor: Andrew Yee, MD • Aim: Disease control
Last updated May 17, 2026 02:06 UTC
-
New hope for elderly myeloma patients: talquetamab trial opens
Disease control Recruiting nowThis study tests a drug called talquetamab in elderly patients whose multiple myeloma has come back after earlier treatments. The drug is given as a shot under the skin and aims to help the body's immune cells attack the cancer. If the drug stops working, another drug called dara…
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE2 • Sponsor: Larysa Sanchez • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
New combo aims to crush hard-to-treat myeloma
Disease control Recruiting nowThis study tests whether adding the drug selinexor to standard bispecific antibody therapy can help people with multiple myeloma that has come back or stopped responding to other treatments. About 27 adults will receive the combination for up to 12 months. The main goals are to c…
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE2 • Sponsor: Duke University • Aim: Disease control
Last updated May 17, 2026 01:59 UTC
-
Engineered immune cells take on Hard-to-Treat blood cancer
Disease control Recruiting nowThis early study tests a new treatment called BCMA-UCART for adults with multiple myeloma that has come back or not responded to other therapies. The treatment uses donor immune cells that are specially designed to find and attack cancer cells. The goal is to see if it is safe an…
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: NA • Sponsor: Bioray Laboratories • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Gene therapy builds Cancer-Killing cells inside you – no lab needed
Disease control Recruiting nowThis early-stage study tests a new gene therapy called KLN-1010 for people with multiple myeloma that has returned or not responded to treatment. Instead of removing cells, modifying them in a lab, and putting them back, this therapy aims to create cancer-fighting CAR-T cells dir…
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE1 • Sponsor: Kelonia Therapeutics, Inc. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New hope for hard-to-treat myeloma: triple-drug combo enters phase 2 trial
Disease control Recruiting nowThis study tests a new drug called inobrodib combined with two standard medicines (pomalidomide and dexamethasone) in 100 adults whose multiple myeloma has come back or no longer responds to available therapies. The goal is to see how well the combination shrinks or controls the …
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE2 • Sponsor: CellCentric Ltd. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New CAR t therapy targets Hard-to-Treat myeloma
Disease control Recruiting nowThis early-phase study tests a new treatment called TriPRIL CAR T cells for people with multiple myeloma that has come back or not responded to standard therapy. The main goal is to check safety and side effects in 18 adults. Participants first receive chemotherapy to prepare the…
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE1 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
New Dual-Target CAR t therapy takes on Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase study tests a new type of cell therapy (BCMA-CD19 cCAR) in 12 people with multiple myeloma or plasmacytoid lymphoma that has come back or not responded to standard treatments. The main goal is to check safety and side effects. Participants receive a single infusi…
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE1 • Sponsor: iCell Gene Therapeutics • Aim: Disease control
Last updated May 05, 2026 11:53 UTC
-
Can early palliative care boost quality of life for blood cancer patients?
Symptom relief Recruiting nowThis study looks at whether adding early palliative care to usual treatment helps people with multiple myeloma or aggressive lymphoma feel better. About 144 patients and their caregivers will either get early palliative care or standard care alone. Researchers will track quality …
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated May 17, 2026 02:05 UTC